Key Insights

Highlights

Success Rate

90% trial completion (above average)

Published Results

29 trials with published results (31%)

Research Maturity

53 completed trials (57% of total)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 17/100

Termination Rate

6.5%

6 terminated out of 93 trials

Success Rate

89.8%

+3.3% vs benchmark

Late-Stage Pipeline

32%

30 trials in Phase 3/4

Results Transparency

55%

29 of 53 completed with results

Key Signals

29 with results90% success

Data Visualizations

Phase Distribution

77Total
Not Applicable (26)
Early P 1 (1)
P 1 (3)
P 2 (17)
P 3 (19)
P 4 (11)

Trial Status

Completed53
Unknown16
Recruiting7
Terminated6
Active Not Recruiting4
Withdrawn4

Trial Success Rate

89.8%

Benchmark: 86.5%

Based on 53 completed trials

Clinical Trials (93)

Showing 20 of 20 trials
NCT02975310Not ApplicableRecruiting

In-clinic Endoscopic Polypectomy for Chronic Sinusitis With Nasal Polyps

NCT02533206Not ApplicableActive Not Recruiting

Pilot Study of The EPIC Trial

NCT07268313Phase 4RecruitingPrimary

Complete Remission After Treatment With Biologics for Nasal Polyps

NCT05274750Phase 3CompletedPrimary

Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps

NCT06639295Phase 3Active Not Recruiting

A Study to Evaluate 611 in Patients With Chronic Rhinosinusitis With Nasal Polyps

NCT07245329Not ApplicableRecruitingPrimary

Effect of Full-House ESS With Nasopharyngeal Lymphoid Tissue Ablation on Nasal Polyps

NCT05672030CompletedPrimary

Role of IL-5R Signaling in Non-eosinophil Upper Airway Cells in CRSwNP

NCT06824649Phase 4Not Yet Recruiting

Biologics in Chronic Rhinosinusitis With Nasal Polyposis

NCT05575037Phase 2Active Not RecruitingPrimary

Mechanisms of Benefit of IL4RA Inhibition in Aspirin-Exacerbated Respiratory Disease

NCT04852562Not ApplicableCompleted

The Effect of Modified Radical Endoscopic Sinus Surgery on Eosinopilic Chronic Rhinosinusitus With Nasal Polyps

NCT05281523Phase 3CompletedPrimary

Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps (ANCHOR-2)

NCT05009758Not ApplicableRecruiting

Moving Towards Precision Medicine in United Airways Disease: Unraveling Inflammatory Patterns in Asthmatic Patients With or Without Nasal Polyps

NCT06036927Phase 2Completed

A Clinical Study of TQC2731 Injection in the Treatment of Chronic Rhinosinusitis With Nasal Polyps

NCT05094570Phase 4RecruitingPrimary

Interleukin-4Ra Blockade by Dupilumab Decreases Staphylococcus Colonization and Increases Microbial Diversity in CRSwNP

NCT03704415Not ApplicableCompleted

Aggravated Airway Inflammation: Research on Genomics and Optimal Operative Treatment (AirGOs Operative)

NCT06750471Phase 4Active Not RecruitingPrimary

Dupixent Study for Alternate Administration

NCT04607005Phase 3CompletedPrimary

Efficacy and Safety of Mepolizumab in Adults With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)/ Eosinophilic Chronic Rhinosinusitis (ECRS)

NCT04185012Phase 3CompletedPrimary

NAsal Polyps: Inflammatory & Molecular Phenotyping of Responders to Benralizumab

NCT05287841Not ApplicableRecruiting

Does Batten Grafting Improve Nasal Outcomes in Septoplasty and Turbinate Reduction?

NCT00731185Phase 3CompletedPrimary

Mometasone Furoate Nasal Spray for Treatment of Nasal Polyposis After Surgery (Study P03218)

Scroll to load more

Research Network

Activity Timeline